According to the information obtained from the Zhitong Finance APP, YSB (09885) has risen by more than 11%, reaching a new high since its listing at HKD 28.15, an increase of over 40% compared to the IPO price of HKD 20. As of the time of writing, it has increased by 11.33%, reaching HKD 28, with a turnover of HKD 16,400,900.
AXIN International pointed out that thanks to its strong network effect, the company has become China's largest and rapidly developing out-of-hospital digital pharmaceutical industry service platform. The company's total GMV reached CNY 37.8 billion in 2022, with a CAGR of 38.6% from 2020 to 2022. Both GMV and growth rate rank first among China's out-of-hospital digital pharmaceutical industry service platforms. In addition, the monthly average number of stock keeping units (SKUs) traded on the company's platform is approximately 3.3 million, ranking highest among China's out-of-hospital digital pharmaceutical industry service platforms.
Huatai Securities research report pointed out that the announcement of the Hang Seng Composite Index adjustment list is expected to be made on August 24, 2023, and will officially take effect on September 4. The review period for this round of Hang Seng Composite Index is from July 1, 2022, to June 30, 2023. The bank predicts that the average market capitalization threshold for the inclusion of stocks through the Stock Connect program in this round is approximately HKD 6.1 billion, and has identified 22 potential candidates to be included in the Stock Connect program, including YSB.

09885

YSB rose more than 11%, reaching a new high of HK$28.15 since its listing, an increase of over 40% from the IPO price of HK$20. As of the time of writing, it has risen by 11.33% to HK$28, with a turnover of HK$16,400,900.

Zhitong

YSB rose more than 11%, up more than 40% from the IPO price. Institutions predict that the company is expected to be included in the Hong Kong Stock Connect in early September.